Human leukocyte antigen antibody-incompatible renal transplantation: Excellent medium-term outcomes with negative cytotoxic crossmatch

Transplantation

Volumn 92, Issue 8, 2011, Pages 900-906

  Higgins, Robert ^a,d   Lowe, David ^b   Hathaway, Mark ^b   Williams, Clare ^b   Lam, For T ^a   Kashi, Habib ^a   Tan, Lam Chin ^a   Imray, Chris ^a   Fletcher, Simon ^a   Chen, Klaus ^a   Krishnan, Nithya ^a   Hamer, Rizwan ^a,c   Daga, Sunil ^a,c   Edey, Matthew ^a,c   Zehnder, Daniel ^a,c   Briggs, David ^b  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY HOSPITAL COVENTRY   (United Kingdom)

Author keywords

Antibody incompatible transplantation; Antibody mediated rejection; Antithymocyte globulin.; HLA antibodies; Plasmapheresis

Indexed keywords

BASILIXIMAB; ECULIZUMAB; GANCICLOVIR; HLA ANTIBODY; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIAL INFECTION; BK VIRUS; CANCER RADIOTHERAPY; CAPILLARY LEAK SYNDROME; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEATH; DRUG MEGADOSE; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HISTOINCOMPATIBILITY; HLA MATCHING; HUMAN; HYPOTENSION; INTESTINE INFARCTION; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MYCOSIS; PLASMAPHERESIS; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECTUM CARCINOMA; RENAL REPLACEMENT THERAPY; SEPSIS; SINGLE DRUG DOSE; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TESTIS CANCER; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEINURIA; TISSUE DONORS;

EID: 80054742066     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31822dc38d     Document Type: Article

References (25)

1. Palmer A, Taube D, Welsh K, et al. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989; 1: 10.
2. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887.
3. Higgins RM, Bevan DJ, Carey BS, et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996; 348: 1208.
4. Montgomery RA, Hardy MA, Jordan SC, et al. Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation 2004; 78: 181.
5. Higgins R, Briggs D, Clarke B, et al. Antibody incompatible transplantation. The British Transplantation Society 2006. Available at: Www.bts.org.uk. Accessed July 2011.
6. Higgins RM, Hudson A, Johnson RJ, et al. UK registry of antibody incompatible transplantation 2001-2010. Transplantation 2010; 90(suppl 2S): 189.
7. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256.
8. Gupta A, Iveson V, Varagunam M, et al. Pretransplant donor-specific antibodies in cytotoxic negative XM kidney transplants: Are they relevant? Transplantation 2008; 85: 1200.
9. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398.
10. Singh N, Djamali A, Lorentzen D, et al. Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes. Transplantation 2010; 90: 1079.
11. Bächler K, Amico P, Hönger G, et al. Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor- specific HLA antibodies. Am J Transplant 2010; 10: 1254.
12. Willicombe M, Brookes P, Santos-Nunez E, et al. Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2011; 11: 470.
13. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody.AmJ Transplant 2006; 6: 346.
14. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582.
15. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: Longer-term outcomes. Am J Transplant 2009; 9: 536.
16. West-Thiekle P, Herren H, Thiekle J, et al. Results of positive crossmatch transplantation in African American renal transplant recipients. Am J Transplant 2008; 8: 348.
17. Aklain E, Dinavahi R, Friedlander R, et al. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 2008; 3: 1160.
18. Thirkle JJ, West-Theikle PM, Herren HL, et al. Living donor kidney transplantation across positive crossmatch; the University of Illinois at Chicago experience. Transplantation 2009; 87: 268.
19. Mai ML, Ahsan N, Wadei HM, et al. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin. Transplantation 2009; 87: 227.
20. Higgins R, Zehnder D, Chen K, et al. The histological development of acute antibody-mediated rejection in HLA antibody-incompatible renal transplantation. Nephrol Dial Transplant 2010; 25: 1306.
21. Kosmoliaptsis V, O'Rourke C, Bradley JA, et al. Improved Luminexbased human leukocyte antigen-specific antibody screening using dithiothreitol- treated sera. Hum Immunol 2010; 71: 45.
22. Higgins R, Lowe D, Hathaway M, et al. Double filtration plasmapheresis in antibody-incompatible kidney transplantation. Ther Apher Dial 2010; 14: 392.
23. Higgins R, Lowe D, Hathaway M, et al. Rises and falls in donor-specific and third-party HLA antibody levels after antibody incompatible transplantation. Transplantation 2009; 87: 882.
24. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095.
25. Higgins R, Hathaway M, Lowe D, et al. Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: Resolution of rejection in the presence of circulating donor-specific antibody. Transplantation 2007; 84: 876.